Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients

Astria Therapeutics Inc. (NASDAQ:ATXS) is one of the stocks under $10 to buy now. Earlier on June 13, Astria Therapeutics announced positive initial results from the ALPHA-SOLAR long-term open-label trial of navenibart (STAR-0215) in hereditary angioedema/HAE patients. These findings were presented at the European Academy of Allergy and Clinical Immunology/EAACI Annual Congress.

The trial showed an overall reduction in the monthly HAE attack rate, with a 92% mean and 97% median reduction. These results support the potential for every three-month and every six-month dosing regimens for navenibart, as well as its favorable safety and tolerability profile. These initial results from ALPHA-SOLAR are consistent with the “best-in-class” profile observed in the earlier ALPHA-STAR Phase 1b/2 trial.

Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients

A closeup of pills in a pharmacy, representing the high quality medications of the company.

The ALPHA-SOLAR trial is a long-term, open-label study designed to assess the safety and efficacy of navenibart in adults with HAE Type 1 or 2. All 16 target enrollment participants from the Phase 1b/2 ALPHA-STAR trial opted to enroll in ALPHA-SOLAR. Patients from ALPHA-STAR Cohorts 1 and 2 joined Arm A, while Cohort 3 patients joined Arm B.

Astria Therapeutics Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for allergic and immunological diseases in the US.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.